Shawn Cross - 27 Dec 2023 Form 4 Insider Report for Cyclo Therapeutics, Inc. (CYTH)

Role: Director
Signature: /s/ Shawn Cross
Issuer symbol: CYTH
Transactions as of: 27 Dec 2023
Transactions value $: $0
Form type: 4
Filing time: 28 Dec 2023, 21:50:39 UTC
Previous filing: 24 Nov 2023
Next filing: 05 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CYTH	Common Stock	Award	$0	+72.6K		$0.00	72.6K	27 Dec 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CYTH	Stock Option (Right to buy)	Award	$0	+88.9K	+8891%	$0.00	89.9K	27 Dec 2023	Common Stock	88.9K	$2.96	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On September 21, 2023, Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. ("Merger Sub"), and Applied Molecular Transport, Inc. ("AMTI") entered into an Agreement and Plan of Merger (the "Merger Agreement"), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into AMTI, with AMTI continuing as a wholly owned subsidiary of Cyclo and the surviving corporation of the merger (the "Merger"). Upon the effective time of the Merger on December 27, 2023, the Reporting Person received shares of Cyclo common stock in exchange for shares of AMTI common stock and options to acquire shares of Cyclo common stock in exchange for options to acquire shares of AMTI common stock, each based on the exchange ratio determined by the Merger Agreement. All AMTI restricted stock units held by the Reporting Person were fully settled prior to the effective time of the Merger.
F2	The options were fully vested upon the closing of the Merger Agreement.

Content

On September 21, 2023, Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. ("Merger Sub"), and Applied Molecular Transport, Inc. ("AMTI") entered into an Agreement and Plan of Merger (the "Merger Agreement"), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into AMTI, with AMTI continuing as a wholly owned subsidiary of Cyclo and the surviving corporation of the merger (the "Merger"). Upon the effective time of the Merger on December 27, 2023, the Reporting Person received shares of Cyclo common stock in exchange for shares of AMTI common stock and options to acquire shares of Cyclo common stock in exchange for options to acquire shares of AMTI common stock, each based on the exchange ratio determined by the Merger Agreement. All AMTI restricted stock units held by the Reporting Person were fully settled prior to the effective time of the Merger.

The options were fully vested upon the closing of the Merger Agreement.